Effect of Pioglitazone on Intima Media Thickness, Endothelial Function and Heart Rate Variability in Patients with Impaired Glucose Tolerance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004421-26-DE

Enrollment

120

Registered

2006-03-08

Start date

2006-07-18

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance

Interventions

Product Name: Pioglitazone Product Code: none Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Impaired glucose tolerance 40-75 years of age Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Diabetes mellitus Heart Failure Pretreatment with glitazones or statins

Design outcomes

Primary

Measure	Time frame
Main Objective: Assessment of influence of pioglitazon vs. simvastatin vs. pioglitazon+simvastatin on intima media thickness;Secondary Objective: Assessment of heart rate variability Non-invasive assessment of endothelial function (flow mediated dilatation A. brachialis) Assessment of metabolic and vascular lab parameters ;Primary end point(s): Change in intima media thickness	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026